Key result
Argatroban combined with DAPT reduced the proportion of early neurological deterioration compared to DAPT alone (4.2% vs. 10.0%, adjusted p=0.046) in acute mild to moderate ischemic stroke.
Why the study?
While DAPT benefits acute ischemic stroke with large artery atherosclerosis etiology, the effect of adding an anticoagulant to DAPT in this population had not been studied.
Does argatroban plus DAPT prevent early neurological deterioration in patients with acute mild to moderate ischemic stroke with large artery atherosclerosis compared to DAPT alone?
Cohort (n=649)
Does argatroban plus DAPT prevent early neurological deterioration in patients with acute mild to moderate ischemic stroke with large artery atherosclerosis compared to DAPT alone?
Absolute Event Rate: 4.2% vs 10%
p-value: p=0.046
Short-term argatroban combined with DAPT appears safe and may effectively prevent early neurological deterioration and improve neurological prognosis in acute mild to moderate ischemic stroke with large artery atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Argatroban plus DAPT was associated with fewer early deteriorations in this cohort; leaves open need for randomized confirmation before practice change.
Li et al. (2022) conducted a cohort in acute mild to moderate ischemic stroke with large artery atherosclerosis (n=649). Argatroban plus dual antiplatelet therapy (DAPT) vs. DAPT only was evaluated on proportion of early neurological deterioration (END) (p=0.046). Argatroban combined with DAPT reduced the proportion of early neurological deterioration compared to DAPT alone (4.2% vs. 10.0%, adjusted p=0.046) in acute mild to moderate ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: